Stock screener

CHRS

Conviction 42HealthcareScan · Fri, Jun 26, 2026
CHRS$1.49+0.68%
ResistanceSupportVol 14
63 bars
Vol MA14 855.7K
Mar 27Apr 15May 4May 20Jun 9Jun 26
Coherus Oncology, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.coherus.com
Price1.49
Change+0.68%
Gap+0.68%
Rel volume2.72×
Avg volume900.47K
Avg $ vol1.33M
SMA 201.46
SMA 501.62
SMA 2001.61
Price vs 50-8.16%
Price vs 200-7.45%
MA stackmixed
50/200 cross
Supertrenddown · 1.63
RSI (14)48
MACD hist0.02
MACD crossbull · 5d
Stoch %K / %D68 / 68
ADX (14)12
+DI / −DI22 / 19
RSI divergence
MACD divergence
ATR %+6.19%
ADR %5.76%
52w high2.51
52w low0.7313
From 52w high-40.64%
Above 52w low+103.75%
New 52w highNo
SqueezeOff
Bollinger width18.50%
%B0.60
Donchian pos46.38%
Donchian high1.68
Donchian low1.33
AVWAP (52w high)1.80
vs AVWAP high-17.05%
AVWAP (52w low)1.56
vs AVWAP low-4.79%
OBV trendFlat
Chaikin MF (20)-0.28
Today vs 20d2.72×
Avg vol (14d)855.7K
Avg vol (20d)900.47K
Avg $ vol (20d)1.33M
Market cap
RS 3m (vs SPY)-28.18%
RS 6m (vs SPY)-1.51%
RS line new highNo
Trend template3/8
Technical rank39.5
1 week+0.68%
1 month-10.24%
3 months-10.24%
6 months+12.88%
1 year+106.66%
YTD+8.76%
P/E1.36
P/B2.90
P/S
P/FCF-1.64
EPS1.43
Div yield
ROE213.71%
ROA63.16%
Debt/Eq0.94
Current1.56
EV/EBITDA-1.04
Gross margin
Net margin
Rev growth-100.00%
EPS growth489.41%
Price target
Target upside
Analyst rating
Institutional
Ent. value186.71M
Revenue1.4M
Net income-38.33M
Gross profit
Free cash flow-138.8M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out154.25M
Employees145
ListedThu, Nov 6, 2014
Free float
Float %
Short interest
Days to cover
Short volume
Squeeze score
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction42 / 100
Pattern quality
Tech rank39.5 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance1.99
Support1.33
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CHRS

All disclosures →
No recent disclosed trades by Congress in CHRS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CHRS · 10 buys

InsiderSideShares
O'Donnell-Tormey Jill
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Wahlstrom Mats
Director · Common Stock · 2026-06-05
Grant30K
Karachun Rita A
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Wahlstrom Mats
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Newcomer Lee Nisley
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Satvat Ali J.
Director · Common Stock · 2026-06-05
Grant30K
Newton Charles W.
Director · Common Stock · 2026-06-05
Grant30K
Satvat Ali J.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Ryan Michael Lee
Director · Common Stock · 2026-06-05
Grant30K
Newton Charles W.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K

SEC filings

EDGAR filings in CHRS · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.